Synlait Milk Limited confirms extended product release times and supply chain disruptions following The a2 Milk Company's update on its China infant formula business. The company maintains no FY26 guidance amid persistent industry risks.
- Enhanced testing delays infant formula product releases
- Supply chain challenges continue despite production recovery
- No FY26 financial guidance due to volatile market conditions
- Rebuilding customer inventory after manufacturing setbacks
- Industry risks include regulatory shifts and geopolitical tensions
Testing and Supply Chain Strains Stretch Working Capital
Synlait Milk Limited (NZX:SML, ASX:SM1) has confirmed that enhanced testing protocols introduced earlier this year for all infant formula products have extended release times, complicating working capital management. This development follows The a2 Milk Company’s recent update on its infant milk formula operations in China, which referenced Synlait’s role as a supplier.
The extended testing regime reflects heightened quality assurance measures but has resulted in delays that ripple through Synlait’s supply chain and cash flow cycles. The company is actively managing these impacts with support from The a2 Milk Company, aiming to stabilise operations amid a turbulent market.
Production Levels Recovering, Inventory Rebuilding Underway
After previously reported manufacturing challenges, Synlait says production has returned to targeted levels. The focus now is on replenishing customer inventories, which were depleted during the disruption. This recovery is critical as the infant formula market in China remains highly dynamic, with fluctuating demand and regulatory pressures.
Despite this progress, Synlait reiterates its decision not to provide full-year FY26 financial guidance, citing ongoing uncertainties. These include variable product release and clearance times, supply chain complexities, and a challenging geopolitical and regulatory environment that continues to affect the global infant formula sector.
Industry Risks Persist Amid Regulatory and Geopolitical Headwinds
Synlait’s cautious stance underscores the broader risks facing infant formula producers operating in China and globally. Regulatory changes and geopolitical tensions are creating a volatile backdrop for supply chains and market access. The company’s half-year results in March 2026 and full-year results in September 2025 both highlighted these challenges, which remain unresolved.
This update from Synlait, prompted by The a2 Milk Company’s announcement, highlights the fragility of supply chain recovery and the ongoing need for operational resilience. Investors will be watching closely for signs of sustained stability or further disruption in this key sector.
Bottom Line?
Synlait’s ongoing supply chain and testing delays signal that recovery in the infant formula market remains fragile, warranting close attention to future operational updates.
Questions in the middle?
- How will extended testing protocols affect Synlait’s cash flow and margins over the coming quarters?
- What regulatory developments in China could further impact Synlait’s supply chain and market access?
- Can Synlait and The a2 Milk Company fully restore customer inventory levels without additional disruption?